Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) covers the month of April 2019, specifically dated April 11, 2019. The registrant is a foreign private issuer based in Melbourne, Australia, filing pursuant to Rule 13a-16 under the Securities Exchange Act of 1934. The primary purpose of this report is to disclose an Initial Director's Interest Notice under ASX Listing Rule 3.19A.1.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director interests and does not contain financial statements or performance metrics.
Material Changes
- Director Appointment: Tristan Edwards was appointed as a Director on April 8, 2019.
- Securities Interest: The filing discloses that the newly appointed director holds no relevant interests in the company's securities (neither as a registered holder nor otherwise) and has no interests in contracts with the company.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the statutory disclosure of the director's lack of financial interest in the entity at the time of appointment.
Investor Verification Checklist
- Verify the appointment date of Tristan Edwards as Director (April 8, 2019).
- Confirm that the director holds zero notifiable interests in Alterity Therapeutics Limited securities.
- Check subsequent filings for any changes in director interests or financial performance updates, as this 6-K contains no financial data.